Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Phase 2Recruiting
- Sponsor
- ALX Oncology
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of evorpacept in breast cancer, sponsored by ALX Oncology. Primary endpoint: Overall Response Rate at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
evorpacept
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07007559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007559.